J Am Pharm Assoc (2003). 2013 Sep-Oct;53(5):539-44. doi: 10.1331/JAPhA.2013.13019.
To describe acceptance of systematic and organized pharmacist interventions to address simvastatin safety concerns.
University of Utah Redwood Health Center and Pharmacy, June 2011 to February 2012.
Redwood Health Center is an outpatient multispecialty clinic associated with University of Utah Health Care with approximately 85,000 annual visits between primary care and specialty practices. In addition to filling approximately 175,000 prescriptions per year, pharmacists provide disease management and education under collaborative practice agreements.
All patients identified as being treated outside the revised simvastatin labeling were included (n = 158). After pharmacist review, recommendations were made to providers via the electronic medical record to promote adherence with the June 2011 Food and Drug Administration (FDA) safety guidelines. In addition to recommendations regarding the FDA guidelines (n = 76), additional recommendations were made to optimize treatment based on low-density lipoprotein cholesterol goal or laboratory evaluation (n = 25).
Acceptance rate of recommendations and resources needed to provide pharmacist interventions.
Recommendations were accepted 92% of the time without modification and 7% of the time with modification. Total pharmacist time to conduct the interventions was 21.5 hours, and 3.9 hours of technician time were spent contacting patients.
Targeted pharmacist interventions were effective in promoting adherence with this complex medication safety alert. A standardized, comprehensive approach to patient assessment, including use of evidence to support pharmacist recommendations, resulted in a high level of acceptance by prescribers.
描述接受系统和有组织的药剂师干预措施来解决辛伐他汀安全性问题的情况。
犹他州红杉健康中心和药房,2011 年 6 月至 2012 年 2 月。
红杉健康中心是一家与犹他大学医疗保健系统相关的多专业门诊诊所,每年有大约 85000 次初级保健和专科就诊。除了每年大约 175000 张处方外,药剂师还根据合作实践协议提供疾病管理和教育。
所有被确定为接受不符合修订后辛伐他汀标签规定治疗的患者均被纳入(n=158)。在药剂师审查后,通过电子病历向提供者提出建议,以促进遵守 2011 年 6 月美国食品和药物管理局(FDA)的安全指南。除了关于 FDA 指南的建议(n=76),还根据低密度脂蛋白胆固醇目标或实验室评估提出了优化治疗的额外建议(n=25)。
建议接受率和提供药剂师干预所需的资源。
建议接受率为 92%,无需修改,7%需要修改。药剂师完成干预措施的总时间为 21.5 小时,联系患者的技术员时间为 3.9 小时。
有针对性的药剂师干预措施在促进遵守这一复杂药物安全警报方面是有效的。对患者评估采用标准化、全面的方法,包括使用证据来支持药剂师的建议,从而使处方者的接受度很高。